Controversies in Neurology
July 2005

Mild Cognitive Impairment as a Clinical Entity and Treatment Target

Author Affiliations

Author Affiliations: Alzheimer’s Disease Research Center, Mayo Clinic College of Medicine, Rochester, Minn (Dr Petersen); Alzheimer’s Disease Research Center, Washington University School of Medicine, St Louis, Mo (Dr Morris).




Copyright 2005 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.2005

Arch Neurol. 2005;62(7):1160-1163. doi:10.1001/archneur.62.7.1160

Mild cognitive impairment (MCI) has been actively investigated for the past decade.1,2 The term was coined in the late 1980s by the New York University group to identify individuals who were not cognitively normal for age and yet did not have overt dementia, and their outcomes were described in an article examining predictors of dementia by Flicker et al3 in the early 1990s. Flicker et al characterized MCI as equivalent to a Global Deterioration Scale rating of 3 and found that a diagnostic approach combining a careful, structured interview and the appropriate neuropsychological tests can discriminate those individuals with MCI likely to experience cognitive deterioration from those with a benign prognosis.3

First Page Preview View Large
First page PDF preview
First page PDF preview